publication date: Nov 7, 2011
|
author/source: Definiens
Definiens®, the leading Health Image
Intelligence
™ company, today announced the release of its new
Quantitative
Digital Pathology portfolio, designed to advance translational research in
pathology, specifically in biomarker development. The new portfolio will offer
updated versions of Definiens Tissue Studio®, Definiens Developer XD™ as well
as the introduction of a novel component, Definiens Image Miner™.
The technology in Definiens' recently
released product suite will provide high accuracy in automatically identifying
relevant structures of interest and specific morphology in histology, resulting
in a detailed phenotypic fingerprint and biomarker expression profile on a
cell-by-cell basis. The large set of descriptors can be correlated against
therapy response or patient outcome with the goal of identifying new types of
biomarkers of predictive or prognostic value.
Definiens Image Miner
™ 1, the novel
technology component in this product portfolio, closely integrates data mining
with image analysis to accelerate biomarker research. The data mining
functionality is based on the same revolutionary Cognition Network Technology
used in Definiens' well-established image analysis solutions. Definiens Image
Miner
TM 1 provides a substantial productivity increase when profiling tissue
probes for clinically or diagnostically relevant differences in morphology or
biomarker expression. Development and quality control are supported by seamless
links between data points and the visual inspections of associated regions in
the tissue.
"We expect the tight integration of our new
data-mining engine with the significantly updated image analysis solutions to
substantially increase productivity and assay quality in tissue-based biomarker
development," says Dr. Martin Baatz, Vice President of Marketing at Definiens.
"We consider this a major step on the way to turning pathology into a
quantitative discipline."
Also included in the new portfolio is
Definiens Developer XD
™ 2, the most powerful development environment for
automated image analysis that addresses a wide scope of functions in biomedical
image analysis with unprecedented depth and accuracy. Developer XD™
2 will be
the solution of choice for highly advanced or customized analysis tasks of
digital tissue slides. This updated version addresses a series of requirements
suggested by the user community including very large data processing and
machine learning functionality.
The highly popular product of the suite is
Definiens Tissue Studio® 3, which is an updated version of the company's
leading Image Analysis Solution for Quantitative Digital Pathology. It combines
highly detailed quantification of tissue specimen with a straightforward and
fast out-of-the-box configuration workflow. New features include an improved
detection of regions of interest, classification of nuclear morphology and an
angiogenesis module.
After exploring the new Definiens Tissue
Studio® 3 during the early access program, Mark Lloyd, Supervisor of Analytical
Microscopy Core Facility at Moffitt Cancer Center, says: "I can be difficult to
please regarding image analysis of histological samples, but this is the best
commercial product I have used to date. This includes workflow and usability,
as well as function and flexibility." And Dr. Tom Nifong, VP CLIA Services at
Metamark Genetics, adds: "The Composer Technology for automatic detection of
regions of interest performed great. It was able to identify tumor, stroma and
artifacts in my fluorescence samples. I was really impressed by the improvement
in accuracy and speed of the nucleus detection. Fantastic job!"
For more information about the new products,
please visit
quantitative-digital-pathology.definiens.com
About Definiens
Definiens is a leading Health Image
Intelligence
™ company that develops software solutions for biomedical image
analysis, data mining and clinical decision support. The company's software
analyzes images from cell-based assays, whole tissue slides and full body scans
and allows users to correlate this information with data derived from other
sources. By automating analysis workflows and generating new knowledge,
Definiens provides pharmaceutical and biotechnology companies, research
institutions, clinical service organizations and medical professionals with
deeper insights, faster results and better decision support. Harnessing the
power of image intelligence, Definiens supports the development of personalized
medicine and aims to significantly improve the quality of patients' lives.
Definiens is headquartered in Munich, Germany,
and has offices throughout the United States. Further information is available
at
www.definiens.com